VERAXA Biotech Begins Trading on NASDAQ Following Business Combination with Voyager Acquisition Corp.

VERAXA Biotech (NASDAQ: VRXA) has commenced trading on the NASDAQ Capital Market under the ticker symbol ‘VRXA’ as of June 11, 2026, following the successful conclusion of a business combination with Voyager Acquisition Corp. The company is now positioned as a ‘One to Watch’ in the biotechnology sector, focusing on the discovery and development of antibody-based therapeutics for solid tumors.

VERAXA is advancing a diversified oncology pipeline that spans monoclonal antibodies, antibody-drug conjugates (ADCs), bispecific ADCs, and proprietary BiTAC-based therapeutic formats across multiple cancer indications. The company’s proprietary BiTAC platform is designed to conditionally activate therapeutic activity at tumor sites, with the goal of improving target specificity while reducing off-tumor toxicity. This approach addresses a critical challenge in oncology: delivering potent therapies directly to cancer cells while sparing healthy tissue.

Through its focus on ADCs and T-cell engagers (TCEs), VERAXA is positioned within two rapidly growing segments of the global oncology therapeutics market. The ADC market alone is projected to reach significant valuations in the coming years, driven by the success of approved therapies and the promise of next-generation conjugates. Additionally, via selected partnerships, VERAXA aims to contribute value to developments in complementary therapeutic sectors such as radioimmunoconjugates (RICs) and antibody-oligonucleotide conjugates (AOCs). These collaborations could expand the company’s reach beyond its core pipeline and leverage external expertise in emerging modalities.

The listing on NASDAQ provides VERAXA with access to capital markets to fund its research and development efforts. However, as with any early-stage biotechnology company, the path forward involves risks and uncertainties. The company’s forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995, highlight that actual results may differ materially from expectations due to factors such as clinical trial outcomes, regulatory approvals, and competitive dynamics. Investors are advised to review the risk factors detailed in the company’s filings with the SEC, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q.

For more information on the terms of use and disclaimers related to this content, please refer to the InvestorBrandNetwork website at http://IBN.fm/Disclaimer. This announcement underscores the growing interest in innovative oncology platforms that aim to improve the therapeutic index of cancer treatments, a key area of focus for investors and researchers alike.

This news story relied on content distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is VERAXA Biotech Begins Trading on NASDAQ Following Business Combination with Voyager Acquisition Corp..

The post VERAXA Biotech Begins Trading on NASDAQ Following Business Combination with Voyager Acquisition Corp. appeared first on citybuzz.